# Celiac Disease

Diagnose celiac disease while the patient is consuming gluten, using tTG-IgA plus total IgA first. In adults, confirm positive serology with properly sampled duodenal biopsies, then use a strict gluten-free diet, dietitian-led exposure review, and targeted reassessment for persistent symptoms or villous atrophy.

**Clinical question:** How should physicians diagnose, confirm, treat, and monitor celiac disease while identifying nonresponsive or complicated disease?

Updated: 2026-08-24T17:25:56.357869+00:00

## What matters in practice
- Order tTG-IgA with total serum IgA as the initial diagnostic evaluation, and keep the patient on a gluten-containing diet until testing is complete. [6][14]
- Adults generally require upper endoscopy with duodenal biopsies to establish the diagnosis; pediatric no-biopsy pathways do not apply routinely to U.S. adult practice. [6][14]
- A positive celiac serology with normal villi is potential celiac disease, not proof that symptoms are caused by celiac disease; management and follow-up remain clinically controversial. [10]
- After diagnosis, institute a strict gluten-free diet and formal review by a celiac-experienced dietitian; follow symptoms, serology, nutritional status, and correction of baseline laboratory abnormalities. [8][22]
- Persistent symptoms or villous atrophy despite reported adherence requires a structured reassessment for gluten exposure, diagnostic error, competing disorders, and refractory celiac disease. [1][7]

## Test before gluten withdrawal

Serology and histology lose diagnostic utility after gluten restriction.

For a patient with suspected celiac disease, obtain serum tTG-IgA and total serum IgA while the patient continues a gluten-containing diet. This paired approach is the concordant guideline-supported first-line strategy in adults and children because isolated tTG-IgA can be falsely negative with concurrent IgA deficiency. [6][14]

If total IgA is deficient, use IgG-based celiac serology rather than interpreting a negative tTG-IgA as exclusion. Available assays include IgG tTG and IgG deamidated gliadin peptide (DGP); DGP-IgG is particularly useful in early childhood and may identify affected children younger than 2 years when conventional IgA markers are negative. [2][5][13][15]

Do not use native antigliadin antibodies as the principal diagnostic assay. EMA-IgA is highly specific but less sensitive than tTG-IgA in pooled evidence and is most useful as a confirmatory serologic test when results, pretest probability, or a pediatric no-biopsy pathway require greater specificity. [12][13][15]
- A negative tTG-IgA obtained after self-initiated gluten avoidance does not reliably exclude celiac disease; serology, biopsy, and capsule testing other than HLA typing require ongoing gluten exposure. [14]
- Avoid diagnosing celiac disease from HLA-DQ2 or HLA-DQ8 positivity alone: these haplotypes occur in 30% to 40% of Western Caucasian populations, whereas only about 3% of carriers develop disease. [3]
- Use HLA typing as an exclusion-oriented adjunct in selected discordant or gluten-restricted cases, not as routine confirmation in a patient with compatible serology and histology. [3][4][14]

*Serologic test selection should account for total IgA and whether the patient is consuming gluten. [6][13][14]*

| Clinical setting | Preferred test sequence | Interpretation and next step |
| --- | --- | --- |
| Most adults and children | tTG-IgA plus total serum IgA [6] | Positive tTG-IgA with normal total IgA supports celiac disease; in adults, proceed to endoscopy with duodenal biopsy for confirmation. [6] |
| Selective IgA deficiency | Use IgG-based testing, including IgG tTG and/or IgG DGP [13][15] | Do not rely on a negative IgA-based assay; integrate IgG serology with histology when clinical suspicion persists. [2][13] |
| Child younger than 2 years with chronic enteropathy | tTG-IgA plus total IgA; consider DGP-IgG when conventional markers are negative or IgA-based testing is limited [2][6] | Elevated DGP antibodies may identify celiac disease in young children with negative tTG-IgA and EMA-IgA. [2] |
| Already gluten restricted or discordant evaluation | Consider HLA-DQ2/DQ8 typing [3][14] | Absence of the disease-associated haplotypes argues strongly against celiac disease; positivity is not diagnostic. [3][4] |

## When to perform duodenal biopsy

In adults, histologic confirmation remains the usual endpoint of the diagnostic evaluation.

Refer adults with positive celiac serology for upper endoscopy with duodenal biopsies while they remain on gluten. Across current guidelines, endoscopy with duodenal biopsies remains mandatory for a final adult diagnosis, except in limited settings where endoscopy or expert pathology is unavailable. [6]

Interpret pathology with attention to specimen orientation and assessment of well-oriented villous-crypt units. Poor orientation can misclassify villous architecture; morphometric villous-height-to-crypt-depth measurements may improve interobserver agreement compared with non-morphometric assessment. [1]

When tTG-IgA and histology conflict, first confirm that the patient was consuming gluten and that specimens were adequate and correctly interpreted. In adults, repeat small-intestinal biopsy, including jejunal sampling, can be considered for discordant histopathology and tTG-IgA; in children, re-cutting tissue blocks or expert pathology review is generally preferred before repeat endoscopy. [6]
- Do not apply the European pediatric serology-only pathway to routine U.S. adult diagnosis. ESPGHAN criteria use tTG greater than 10 times the upper limit of normal plus EMA and HLA testing, but this approach has not been adopted by U.S. societies. [14][15]
- Positive serology with normal duodenal architecture represents potential celiac disease. Distinguish it from established enteropathy and individualize follow-up because management remains controversial. [10]
- Use wireless capsule endoscopy to assess small-bowel mucosa or complications in complicated celiac disease, not as the standard initial confirmation test when duodenal biopsy is feasible. [9]

*Biopsy is particularly important when the diagnosis will determine lifelong dietary treatment or when test results are discordant. [6][14]*

| Result pattern | Primary concern | Next action |
| --- | --- | --- |
| Positive tTG-IgA, normal total IgA, compatible duodenal injury | Established celiac disease | Initiate a strict gluten-free diet and baseline nutritional assessment. [6][8] |
| Positive tTG-IgA, normal villi | Potential celiac disease, sampling limitation, or another explanation for seropositivity | Verify gluten exposure and biopsy adequacy; use clinical context and planned follow-up rather than assuming symptoms are gluten-mediated. [1][10] |
| Negative serology, compatible clinical suspicion | IgA deficiency, inadequate gluten exposure, or alternative enteropathy | Check total IgA, use IgG-based assays when appropriate, and consider biopsy if suspicion remains high. [6][13][14] |
| Positive serology, nondiagnostic or conflicting histology | Sampling, orientation, interpretation, or true discordance | Obtain expert pathology review; consider repeat small-bowel biopsy in adults. [1][6] |

## Institute a strict gluten-free diet after diagnosis

Dietary treatment must be paired with objective assessment of malabsorption and implementation quality.

Treat confirmed celiac disease with a strict gluten-free diet that excludes gluten-containing foods, beverages, and medications. Complete gluten removal is the cornerstone of management and should lead toward symptomatic, serologic, and histologic remission, although mucosal healing is incomplete in some adults despite symptom resolution and normalized antibodies. [1][22][23]

Refer at diagnosis to a dietitian with celiac-disease and gluten-free-diet expertise. The dietitian should review hidden and inadvertent gluten exposures, practical dietary knowledge, and nutritional adequacy; this intervention is central when symptoms or serologic abnormalities persist. [8]

At baseline and during follow-up, identify nutritional abnormalities and confirm their correction with laboratory testing rather than relying on symptom response. Guidelines emphasize monitoring nutritional status and laboratory abnormalities detected at diagnosis or follow-up because villous recovery and absorptive function do not reliably track with symptoms or antibody normalization. [1][8]
- Document the baseline celiac serology assay and value so the same marker can be trended after treatment. [8][23]
- Do not interpret symptom improvement alone as proof of mucosal recovery; persistent villous injury may occur without symptoms or elevated celiac-related antibody titers. [1]
- For confirmed celiac disease in children and adolescents with diabetes, treatment is a gluten-free diet to prevent complications. [16]

*Core components of post-diagnosis care target dietary exposure, consequences of malabsorption, and complicated disease. [1][8][22]*

| Care domain | Action | Reason to act |
| --- | --- | --- |
| Diet implementation | Begin strict gluten-free diet and arrange celiac-experienced dietitian review. [8][22] | Dietary adherence requires education on gluten-containing foods, beverages, and medications. [22] |
| Serologic follow-up | Trend celiac serology with clinical assessment. [8][23] | Serology contributes to assessment of dietary exposure and disease activity but does not assure mucosal recovery. [1][8] |
| Nutritional follow-up | Measure and recheck laboratory abnormalities identified at diagnosis. [1][8] | Nutritional deficiencies and impaired absorption may persist despite clinical improvement. [1][24] |
| Histologic follow-up | Consider follow-up biopsy when clinical or laboratory findings suggest persistent disease or complications. [1] | Symptoms and antibody normalization do not exclude ongoing villous atrophy. [1] |

## Escalate persistent symptoms or abnormal follow-up findings

Persistent disease after treatment is a diagnostic problem before it is a refractory-celiac diagnosis.

At structured follow-up, reassess symptoms, gluten-free-diet implementation, celiac serology, nutritional status, and correction of baseline laboratory abnormalities. Current follow-up recommendations combine history, serology, and laboratory testing, with celiac-experienced dietitian participation to assess adherence and nutritional adequacy. [8]

Perform follow-up biopsy when strict diet adherence is reported but clinically meaningful symptoms, nutritional abnormalities, or concern for persistent enteropathy remains. Histologic recovery cannot be inferred from negative serology or symptom control; biopsy samples should be adequately oriented and assessed for residual villous injury. [1]

For nonresponsive celiac disease, use a systematic reassessment rather than empirically labeling refractory disease. Confirm the original diagnosis, conduct a detailed gluten-exposure review, reassess histology when indicated, and evaluate competing causes of ongoing symptoms or enteropathy before escalating to a refractory-celiac pathway. [7]
- Treat newly abnormal or persistent nutritional deficits as an indication to reassess both dietary exposure and ongoing absorptive dysfunction. [1][8]
- Use capsule endoscopy when complicated celiac disease requires small-bowel mucosal or complication assessment; it is recommended in guidelines for evaluation of complicated disease. [9]
- Refer suspected refractory celiac disease early to a multidisciplinary center with expertise in complex celiac disease, particularly when persistent villous atrophy is documented despite strict dietary review. [7]

### Nonresponsive versus refractory disease

Nonresponsive celiac disease denotes persistent symptoms, signs, laboratory abnormalities, or enteropathy after a gluten-free diet and requires a broad diagnostic re-evaluation. Refractory celiac disease is a narrower diagnosis that should be considered only after excluding ongoing gluten exposure, diagnostic error, and alternative causes of persistent disease. [7]
- Refractory celiac disease type II warrants particular urgency because recommendations are based largely on retrospective cohorts, small open-label studies, and expert opinion, and because of its association with severe complications including lymphoma. [7][22]
- Use cross-sectional enterography or capsule evaluation selectively when concern exists for small-bowel neoplasm or inflammatory small-bowel pathology in complicated disease. [9][20]

*A stepwise approach prevents premature attribution of persistent symptoms to refractory celiac disease. [1][7][8]*

| Persistent finding | First discriminator | Escalation |
| --- | --- | --- |
| Persistent gastrointestinal or systemic symptoms | Detailed gluten-free-diet review with a celiac-experienced dietitian. [8] | Reconfirm diagnosis and investigate competing causes if exposure review is not explanatory. [7] |
| Ongoing nutritional or laboratory abnormalities | Compare with baseline abnormalities and assess dietary adherence and absorption. [1][8] | Perform follow-up duodenal biopsy when persistent enteropathy is suspected. [1] |
| Negative serology but ongoing symptoms | Do not assume mucosal healing from antibody normalization. [1] | Consider biopsy and evaluation for alternate disease processes. [1][7] |
| Persistent villous atrophy despite strict dietary review | Verify original diagnosis, specimen quality, and ongoing gluten exposure. [1][7] | Refer for expert evaluation of nonresponsive or refractory celiac disease and complications. [7][9] |

## Use targeted testing in high-risk clinical settings

Testing is most useful when a compatible syndrome or high-risk condition creates meaningful pretest probability.

In children and adolescents with type 1 diabetes, celiac disease screening is particularly relevant because most cases are diagnosed within 5 years after diabetes diagnosis. Screening uses celiac serology, including tTG or antiendomysial antibodies, with small-bowel biopsy used to establish the diagnosis when indicated. [17][18]

For patients undergoing upper endoscopy for other reasons, obtain duodenal biopsies when characteristic endoscopic features raise concern for celiac disease. Endoscopic appearance should not replace histologic assessment in adults with suspected disease. [9][6]

Avoid broad reliance on HLA positivity to screen asymptomatic people: DQ2/DQ8 carriage is common and has limited positive predictive value. HLA testing is more clinically useful when its absence can help resolve a difficult diagnostic question. [3][4]
- A tTG-IgA result above 10 times the assay upper limit of normal is part of a pediatric European no-biopsy strategy when supported by EMA and HLA testing, but U.S. practice has not adopted that pathway routinely. [14][15]
- In low-pretest-probability settings, a positive serology should prompt confirmatory evaluation rather than immediate lifelong dietary restriction. [6][14]

*Targeted case finding should direct a diagnostic sequence rather than bypass confirmation. [6][9][17][18]*

| Clinical context | Initial action | Confirmation pathway |
| --- | --- | --- |
| Type 1 diabetes in a child or adolescent | Screen with celiac serology. [17][18] | Use small-bowel biopsy when diagnostic confirmation is required. [18] |
| Compatible symptoms or malabsorption pattern | Order tTG-IgA and total IgA while consuming gluten. [6] | Perform duodenal biopsy in adults with positive serology. [6] |
| Characteristic endoscopic features | Obtain duodenal biopsies during endoscopy. [9] | Interpret with serology, gluten exposure history, and histology quality. [1][6] |
| Uncertain diagnosis after gluten withdrawal | Consider HLA-DQ2/DQ8 testing. [3][14] | Use the result to refine likelihood; a positive result does not establish disease. [3] |

## References
1. Guidelines for best practices in monitoring established ... — www.nature.com — https://www.nature.com/articles/s41575-023-00872-2
2. The anti-deamidated gliadin peptide antibodies unmask celiac disease in small children with chronic diarrhoea - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1590865810003981
3. HLA DQ2 Antigen - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hla-dq2-antigen
4. Function of DQ2 and DQ8 as HLA susceptibility molecules in celiac disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0198885994900795
5. Evaluating diagnostic accuracy of anti-tissue Transglutaminase IgA antibodies as first screening for Celiac Disease in very young children - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S000989811500234X
6. Current guidelines for the management of celiac disease - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8793016
7. Management Strategy for Non-Responsive and Refractory Celiac Disease in Adults: A Review Article — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12525167
8. Follow-Up of Celiac Disease in Adults: “When, What, Who, and Where” — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10181343
9. Review and Critical Appraisal of Clinical Practice Guidelines of Modalities Used in the Diagnosis of Celiac Disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10235591
10. Insights From Potential Celiac Disease as a Paradigm of ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/41881136
11. A systematic review of celiac disease recommendations for ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/42212585
12. Results - Diagnosis of Celiac Disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK344459
13. Digesting all the options: laboratory testing for celiac disease - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/25244521
14. Executive Summary - Diagnosis of Celiac Disease - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK344446
15. Celiac disease: a comprehensive current review - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647104
16. 14. Children and Adolescents: Standards of Medical Care in ... — diabetesjournals.org — https://diabetesjournals.org/care/article/45/Supplement_1/S208/138922/14-Children-and-Adolescents-Standards-of-Medical
17. 14. Children and Adolescents: Standards of Care in Diabetes ... — diabetesjournals.org — https://diabetesjournals.org/care/article/47/Supplement_1/S258/153946/14-Children-and-Adolescents-Standards-of-Care-in
18. Standards of Medical Care in Diabetes—2014 — diabetesjournals.org — https://diabetesjournals.org/care/article/37/Supplement_1/S14/37696/Standards-of-Medical-Care-in-Diabetes-2014
19. Appendix F: Excluded studies - G.1 Review question 4.1 — www.nice.org.uk — https://www.nice.org.uk/guidance/ng20/evidence/appendix-f-excluded-studies-pdf-438530084
20. CT and MR Enterography in the Evaluation of Celiac Disease — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.230122
21. HLA DQ8 Antigen - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/hla-dq8-antigen
22. Gluten-related disorders: monitoring and follow-up - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/B9780128218464000127
23. Follow-up of patients with celiac disease: Achieving compliance with treatment - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016508505001940
24. Nutritional Deficiencies in Celiac Disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0889855307000064

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.